Iovance Biotherapeutics Inc. (IOVA)
IOVA trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$14.50
-0.41% on the day
Market cap
$6.6B
Mid cap
Revenue · 2025
$263.5M
+60.6% on 2024
Net income · 2025
-$391.0M
-148.4% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | IOVA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001425205 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $263.5M |
| Net income | -$391.0M |
| Operating income | -$403.4M |
| Net margin | -148.4% |
| Operating margin | -153.1% |
| Revenue growth | +60.6% |
| Cash | $163.1M |
| Total assets | $913.2M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 24.9× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2026-06-18 |
| Latest annual report | 10-K | 2026-02-24 |
| Latest quarterly / interim | 10-Q | 2026-08-06 |
| Latest current report FORM 8-K | 8-K | 2026-10-05 |
| Latest proxy | DEFA14A | 2026-04-28 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +10.2% |
| 1 month | +52.1% |
| 3 months | +205.5% |
| Year to date | +421.4% |
| 1 year | +565.2% |
| From 52-week high | -3.9% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| IMVT | Immunovant Inc. | $28.71 | -2.61% | $5.9B |
| KOD | Kodiak Sciences Inc | $91.63 | -7.69% | $5.8B |
| CGON | CG Oncology Inc. | $62.40 | -1.16% | $5.5B |
| RGEN | Repligen Corporation | $175.42 | +1.69% | $8.6B |
| SRRK | Scholar Rock Holding Corporation | $40.52 | -3.39% | $4.9B |
| KYMR | Kymera Therapeutics Inc. | $106.68 | -4.82% | $8.9B |
| CRSP | CRISPR Therapeutics AG Common Shares | $50.10 | -2.81% | $4.8B |
| QGEN | Qiagen N.V. Common Shares | $45.44 | +0.29% | $9.4B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier